U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07825259) titled 'A Study of Itraconazole and Posaconazole for Chronic Pulmonary Aspergillosis' on Sept. 11.
Brief Summary: A prospective, randomized, open-label comparative study evaluating oral itraconazole and oral posaconazole in treatment-naive patients with CPA, with treatment for 12 months is proposed. The study will compare clinical effectiveness and safety of the study drugs.
The findings will generate evidence to guide individualized antifungal therapy, inform antifungal stewardship strategies, and strengthen resistance surveillance frameworks for CPA. As the first randomized evaluation of posaconazole in CPA, the study has the potential ...